Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Three Views for Sarepta Therapeutics Inc (SRPT) on Prosensa’s IPO

Page 1 of 2

Sarepta Therapeutics Inc (NASDAQ:SRPT) won’t be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer.  Its one potential challenger on the scene, Prosensa, recently announced plans to move forward with an initial public offering. Here are three views on what a Prosensa IPO could mean for Sarepta.

Sarepta Therapeutics Inc

Prosensa’s IPO won’t have much impact on the progress of its DMD drug, drisapersen. The Dutch biotech didn’t need to raise money to keep development going for the drug. GlaxoSmithKline plc (ADR) (NYSE:GSK) obtained rights to drisapersen back in 2009 and funds the development effort. Similarly, Prosensa doesn’t really need to worry about footing the bill for commercialization of the drug, assuming it ultimately gains regulatory approval. Glaxo will also handle the finances there.

A publicly traded Prosensa doesn’t threaten Sarepta Therapeutics Inc (NASDAQ:SRPT) any more than it would as a privately held company. However, it could possibly have a negative impact on Sarepta’s shares. How? Investors could decide to hedge their bets by buying Prosensa shares (when available) rather than buying more Sarepta stock. This would lessen demand for Sarepta to some extent. Weaker demand would serve as a drag on the stock, keeping it from rising as high as it could reach.

On the other hand, a couple of aspects of Prosensa going public could boost Sarepta Therapeutics Inc (NASDAQ:SRPT)’s shares. The fact that GlaxoSmithKline plc (ADR) (NYSE:GSK) didn’t buy Prosensa is interesting, to say the least. Some investors could read between the lines and suspect that the big pharmaceutical company knows something that makes Prosensa less attractive as an acquisition target. If this proves to be the case, Sarepta Therapeutics Inc (NASDAQ:SRPT) wins.

Prosensa’s SEC filing also raises questions yet again about the safety profile for drisapersen. There have been serious concerns in the past about the protein in the urine of patients taking the drug. In its F-1 document filed in preparation for the IPO, Prosensa mentioned this along with several other adverse effects. The reminder about possible safety issues with drisapersen could make eteplirsen look that much better in the eyes of investors. Of course, the better eteplirsen looks, the better Sarepta looks as an investment alternative.

The third view is that Prosensa’s planned IPO doesn’t matter much at all for Sarepta Therapeutics Inc (NASDAQ:SRPT). After all, Glaxo owns the rights to drisapersen. Whether Prosensa is publicly traded or owned by aliens from another planet shouldn’t really have bearing on what happens with drisapersen.

Another possible twist to this view is that we don’t have to necessarily rule out negative or positive effects on Sarepta Therapeutics Inc (NASDAQ:SRPT)’s stock from the Prosensa IPO. However, under this twist, whatever effects occur will cancel each other out.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!